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ABSTRACT
Over the past few decades, the rise of multidrug resistant (MDR) microorganisms has
grown from an isolated concern to a massive public health crisis. It has become imperative that
scientists look for new ways to combat this issue. Due to the selective pressures of competition,
bacteria and other microbes possess a host of defenses and weapons designed to exploit
vulnerabilities in other microorganisms. Consequently, the study of these systems and microbial
interactions has much to reveal in the search for novel antimicrobial treatments. Previous
research from our laboratory has discovered that both Alcaligenes faecalis and Alcaligenes
viscolactis, two rarely studied and generally non-virulent bacteria, exert a microbicidal effect on
Candida albicans and Staphylococcus aureus, two pathogenic and frequently drug-resistant
organisms. In this study, we confirmed that these effects are via a live-cell, contact-dependent
mechanism and showed that both Alcaligenes species continue to inhibit S. aureus in both
planktonic and biofilm forms of growth. Additionally, we found that A. faecalis and A.
viscolactis have the ability to target Gram-positive bacteria outside the genus Staphylococcus and
certain Gram-negative species as well as Candida glabrata. This study also provides evidence
for the existence of a Type VI Secretion System in both A. faecalis and A. viscolactis, which may
explain their antimicrobial phenotype. Despite efforts to identify the genetic elements involved
via transposon and site-directed mutagenesis, the mechanism of these interactions remain elusive
due to the difficulty of gene transfer in these organisms. We hope these results will increase
current knowledge of Alcaligenes’ capabilities and genetic composition as well as establish the
groundwork for future efforts to discover its inhibitory system and mechanisms.
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INTRODUCTION
History of Antibiotics & Current Antibiotic Crisis
Sir Alexander Fleming’s discovery of Penicillin in 1928 unleashed on the world a
seemingly unstoppable power that helped transform medicine into its modern form as we know it
today [1]. Bacterial infections once devastating to the human body became immediately
vulnerable to these new drugs as an avalanche of new antibiotic classes and derivatives were
discovered, developed, and synthetically modified. While antibiotics have undoubtedly saved
millions of lives since their discovery, their efficacy has been challenged by their intended
targets from the very beginning. In 1940, three years before Penicillin reached mainstream usage
as a treatment, Penicillin-resistant strains of bacteria had already been isolated [1]. In 1962, two
years after the introduction of Methicillin, deadly Methicillin-resistant strains of Staphylococcus
aureus were discovered [1]. While decades of new antibiotic discoveries and advancement have
helped keep this problem at bay, it has now resurfaced in recent years as one of the most pressing
crises of modern medicine for many reasons. A 2013 report by the World Health Organization
declared antibiotic resistance to be a worldwide, catastrophic threat with over 2 million cases and
23,000 mortalities occurring from resistant infections in the United States alone [2].
While antibiotic resistance is an unavoidable product of bacterial evolution and the
selective pressures of exposure to antibiotics, it has been drastically precipitated by inappropriate
prescribing practices, extensive agricultural use, and the collapse of antibiotic research and
development in the pharmaceutical industry due to lack of financial profitability and shortage of
scientific innovation and new discoveries [3]. Consequently, today’s research has begun to shift
to a focus on alternatives to traditional antibiotics including bacteriophage therapy, predatory
bacteria, and bacteriocins [4]. While promising, none have yet been conclusively shown to equal
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the potency of antibiotics [4]. As a result, it is imperative that novel methods of bacterial
inhibition continue to be explored, as is the aim of this thesis.
Development of Antifungal Resistance
Unfortunately, the unopposed expansion of antimicrobial-resistance has not been limited
to antibiotics, but has also penetrated the sphere of antifungal treatment. Unlike antibiotics,
antifungal agents are relatively few in number and even more difficult to develop. As eukaryotes,
both fungi and humans employ similar cellular machinery; therefore, antifungals approved for
clinical application must exhibit high selectivity and low toxicity, ensuring no disruption to the
host’s cells during treatment [5]. Only four major classes of antifungal agents currently exist for
invasive infections: polyenes, flucytosine, azoles, and echinocandins [5]. Since the introduction
of triazoles in the early 1990s, resistance in Candida and Aspergillus species has become a
global threat [6]. Even with treatment, the mortality of patients with fungal infections remains
high, with mortality rates of 30% and 50% for aspergillosis and candidemia patients respectively
[7,8]. Moreover, since 2006, no new classes of antifungals have been approved as of 2015 [8].
Given the paucity of available drugs and the rapid emergence of resistant strains, advancement
and innovation in anti-fungal agents will continue to be an urgent need in the coming years.
Polymicrobial Interactions
One promising area in the search for new mechanisms of microbial inhibition is that of
polymicrobial interactions. Polymicrobial interactions between organisms can be studied several
ways in vitro via liquid co-culture assays, spot test analyses, and biofilm co-cultures, which can
better mimic microbial interactions as they occur in vivo. In recent years, there has been a
growing awareness that microbes rarely live in isolated, planktonic colonies but instead coexist
as complex, biofilm communities composed of bacteria, fungi, viruses, and even archaea [9]. In
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some cases, interactions such as those between Pseudomonas aeruginosa and Staphylococcus
aureus are synergistic, increasing the invasiveness and virulence of infection when present
together [10]. In other cases, the interactions are antagonistic such as in Bdellovibrio and
Micavibrio-style predation, parasitism between bacteriophages and bacteria, competition, or
amensalism [11,12]. Even outside of the human body, microbes such as bacteria often live in
large, heterogenous communities, and competition for resources drives the evolution of many
antimicrobial systems and production of compounds such as ribosomally synthesized peptides or
proteins called bacteriocins [13,14]. With more than 99% of bacterial species producing at least
one bacteriocin, most still unidentified, use of bacteriocins as replacements for antibiotics seems
an incredibly promising area of research [14]. There are still many potential barriers yet to be
overcome. These include the high cost of commercial production, degradation via proteolytic
activity, and narrow spectrum activity for most tested bacteriocins [15]. Fortunately, antagonistic
interactions among microbes are not solely limited to bacteriocin production and therefore
remain a critical area of focus for the exploration of new inhibitory mechanisms [16]. Other
known modes of inhibition include the aforementioned Bdellovibrio-style predation, Type III
secretion systems, and Type VI secretion systems, which will be discussed more in depth later
[17,18,19].
Alcaligenes faecalis
The research involved in this thesis centers on two species of bacteria in the genus
Alcaligenes, the first being Alcaligenes faecalis. A. faecalis is a motile, peritrichous, Gramnegative bacillus found in aqueous environments, soil, and human intestinal flora [20]. It is also
an aerobic, catalase and oxidase positive nonfermenter, though it can grow in anaerobic
conditions in rare cases [21]. These coccoid-shaped rods are 0.5 – 0.6 by 2.0 μm and grow
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optimally at temperatures between 25°C and 37°C, usually occurring singly but occasionally in
pairs or chains [22]. While generally nonpathogenic, A. faecalis can in extremely rare cases
induce nosocomial infections in immunocompromised patients and has been implicated in
chronic otitis, endocarditis, endophthalmitis, and bacteremia, though with mostly favorable
outcomes after treatment [20]. Most recently, a strain of A. faecalis has been found to have
nematicidal effects on Caenorhabditis elegans via an extracellular serine protease virulence
factor [23].
Alcaligenes viscolactis
Unlike its relative, few records of Alcaligenes viscolactis are found in scientific literature.
A. viscolactis is an aerobic, nonmotile, Gram-negative, and almost spherical rod with an optimal
growth temperature of 10°C to 20 °C [24]. It is also found in aqueous environments, and its size
is roughly 0.5-1.0 by 0.8-2.6 μm [24]. Most notably, A. viscolactis is known to produce ropiness
in milk; however, there is no record of pathogenicity in this organism, opportunistic or
otherwise, making it an ideal candidate for potential use as an inhibitor of a variety of pathogenic
organisms [24].
Staphylococcus aureus
Despite its commensal presence in approximately 30% of humans, Staphylococcus
aureus is a common source of nosocomial and community-acquired infections [25]. While it is
most commonly implicated in skin infections such as abscesses and boils, this Gram-positive
coccus possesses a host of virulence factors such as toxins and immunoglobulin-binding proteins
and can cause serious, invasive infections, leading to sepsis and even death [26]. Since the first
appearance of Methicillin-resistant strains of S. aureus (MRSA) over fifty years ago, MRSA has
grown into a worldwide problem, precipitated by its resistance to all available beta-lactam
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antibiotics and failure to identify suitable antigens for vaccine development [25]. Despite a
substantial decline in MRSA bloodstream infections from 2005 to 2012, the decrease has slowed
remarkably since then, with 72,444 cases of invasive MRSA in the U.S. in 2014 [27,28].
Traditionally, severe MRSA infections have been effectively treated with Vancomycin; however,
the rise of Vancomycin intermediate-resistant S. aureus (VISA) and Vancomycin resistant S.
aureus (VRSA) poses a severe threat around the globe [27]. Another key feature of S. aureus is
its ability to form a biofilm composed of polysaccharides, DNA, and protein [29]. These biofilms
can attach to bone, heart valves, and implanted materials, leading to chronic infections [29].
Additionally, S. aureus biofilms decrease the organism’s susceptibility to antibiotics and
weakens immune responses, resulting in increased virulence [29].
Candida albicans
Like S. aureus, the fungi, Candida albicans, is a commensal organism, residing in the
gastrointestinal and genitourinary tracts of approximately 70% of humans [30]. In
immunocompromised patients, C. albicans often becomes an opportunistic pathogen. Candida is
one of the four most common causes of hospital-acquired bloodstream and cardiovascular
infections in the U.S., resulting in mortality rates as high as 50% [30]. C. albicans forms
protective biofilms and has been developing increasingly high levels of resistance to anti-fungal
drugs, a major cause of concern in the medical and scientific communities. It also exhibits
morphological switching, primarily between its yeast and hyphal forms, which plays a critical
role in its virulence [30].
Type VI Secretion Systems
Due to prior observations that Alcaligenes 1) inhibits other organisms via cytolytic effects
2) requires a live-cell, contact-dependent mechanism, and 3) is capable of attacking both
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prokaryotic and eukaryotic organisms, we have hypothesized that the presence of a secretion
system may be implicated in this phenomenon. Although Type III, IV, and VI secretions systems
are able to inject effector molecules directly into other cells via a syringe-like apparatus, many
with microbicidal effects, only the Type VI secretion system (T6SS) has been currently shown to
kill both bacterial and fungal species [31,32]. Since its discovery in Vibrio cholerae, the T6SS
has been found in around 25% of all Gram-negative bacteria [33] and confers an incredible
advantage on organisms competing for resources. While principally thought of as an antibacterial
weapon, the T6SS has many diverse functions and can play an important role in virulence and
pathogenesis, as it does with Pseudomonas aeruginosa in cystic fibrosis patients [33]. More
recently, this system has been shown in Serratia marcescens to target fungal cells, including
those of pathogenic Candida species, in addition to bacterial cells, highlighting its capability as
both an antibacterial and antifungal weapon [34]. T6SS machinery is composed primarily of a
membrane-spanning unit and a tube-like structure that closely resembles a bacteriophage tail. As
the outer sheath contracts, the inner tube and spike propels out of the bacterium and punctures
the membrane of the target organism, delivering effector molecules that lead to disruption or
lysis of the cell [33]. These effector molecules generally target conserved structures such as the
cell wall, membrane compartment, nucleic acids, or cytoskeletal components [33]. Immunity
proteins to specific effector molecules protect the organism from self-destruction [33]. In Vibrio
cholerae, the T6SS is regulated by quorum sensing, catabolite repression, and environmental
conditions, among a host of other factors [35]. It is chromosomally encoded within large,
variable clusters that contain thirteen essential core genes labeled TssA through TssM, which
encode for proteins that form the basic structure of the system [36]. While no T6SS in either A.
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faecalis or A. viscolactis has been previously recorded or characterized in scientific literature,
our observations suggest the possibility that this system or one analogous to it may be involved.
Prior and Present Research
Research in our lab has uncovered several previously unknown features regarding A.
faecalis and A. viscolactis. First, both Alcaligenes species were shown to have apparent
bactericidal effects in a concentration-dependent manner on Staphylococcus aureus,
Staphylococcus epidermidis, and other Staphylococcal species in planktonic form [37].
Additionally, heat-killed and cell-free supernatant tests of A. faecalis and A. viscolactis on S.
aureus were determined to have no inhibitory effect, proving that this phenomenon is dependent
on live Alcaligenes cells and on cell-cell contact [37]. Furthermore, our lab has discovered that
A. faecalis and A. viscolactis also inhibit growth of Candida albicans in both clinical and
laboratory isolates as well as hyphal and yeast-locked strains [38]. This inhibition is dependent
on live-cell interaction, suggesting that the mechanism may likely be the same in the killing of
both Staphylococcal spp. and C. albicans [38]. These discoveries show great potential in
uncovering therapeutic targets for attacking these pathogenic and often drug-resistant organisms
and possibly even for the use of select Alcaligenes strains to kill them directly. For these reasons,
it is highly desirable to uncover the exact mechanism by which Alcaligenes kills its targets.
The objectives of this thesis project were fourfold: 1) to carry out preliminary testing of
A. faecalis and A. viscolactis’ ability to inhibit biofilm growth of S. aureus, 2) to expand our
analysis outside of C. albicans and Staphylococcal species to determine whether other organisms
are susceptible to Alcaligenes, 3) to uncover the genetic elements responsible for this
microbicidal phenotype via random transposon mutagenesis, and 4) ascertain whether
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Alcaligenes contains T6SS machinery and, if present, its potential contribution to our
observations.
MATERIALS AND METHODS
Strains
A. faecalis
ATCC® 8750™

Characteristics
used for biofilm & spot assays, screening for
inhibition, mutagenesis, & genetic analysis

A. viscolactis
Ward’s® # 470179188
S. aureus
ATCC® 25923™

used for biofilm & spot assays, screening for
inhibition, mutagenesis, & genetic analysis

S. aureus
Clinical isolate

used for biofilm assays, screening for
inhibition, obtained from Quillen COM

C. albicans
SC5314

Used for supernatant spot assays

E. coli HB101

host for pRK2013 helper plasmid, used for
triparental mating

Ditta et al. 1980

E. coli BW20767

host for pRL27-Tn5 plasmid, used for
transposon mutagenesis

Nguyen et al. 2016

E. coli SM10λpir

used for biparental conjugation

Plasmids
pRL27
pEX18Gm

Tn5 transposon delivery vector, KanR,
general cloning vector, GmR

Nguyen et al. 2016
Hoang et al. 1998

pEX18Gm containing SOE product deletion of
VgrG gene
Helper plasmid for triparental mating, KanR

This work

pEX18GmΔVgrG
pRK2013

Reference

used for biofilm assays, screening for inhibition

Ditta et al. 1980

Table 1: Primary bacterial strains and plasmids.
Growth Conditions
Unless otherwise noted, all bacterial strains (Table 1) except A. viscolactis were grown in
broth cultures at 37°C on a shaker deck set to 250 RPM. Liquid cultures of A. viscolactis were
grown at laboratory room temperature, approximately 20-25 °C, on a shaker set to 40 RPM
unless co-cultured with other species. Plated cultures were grown under static conditions at the
13

same temperature range. The primary medium for most strains was Luria-Bertani (LB) broth for
liquid cultures and LB agar for plated cultures. Other media and conditions used will be
discussed under their specific protocols.
Alcaligenes - S. aureus Biofilm Interactions
Liquid cultures of A. faecalis, A. viscolactis, laboratory S. aureus, and clinical S. aureus
were prepared via inoculation in 5 mL tubes of LB broth and incubated on a rotary shaker for
approximately 24 hours.
Using a spectrophotometer set to 600 nm (OD600), the absorbance of the overnight
cultures were taken and used to prepare standardized co-cultures with a 10:1 ratio of Alcaligenes
to S. aureus in 5mL LB tubes, along with controls of clinical and laboratory S. aureus alone in
equivalent amounts. One mL of each preparation was pipetted into separate wells on a six well
plate. Additionally, a slide cover slip was placed in one control and one co-culture well. The well
plate was placed in a 37°C incubator for approximately 24 hours.
After incubation, the residual liquid in each well was poured off, and the biofilms
carefully washed once with 1 mL of phosphate buffer solution (PBS). Another 1 mL of PBS was
added to each of the wells, and the biofilm was scraped into the solution with a pipette. Tenfold
serial dilutions of the biofilms were performed using PBS. The dilutions were plated on Mannitol
Salt Agar (MSA), a selective and differential medium used for Staphylococcus species that
prevents Alcaligenes from growing. The MSA plates were subsequently placed at 37°C
overnight, and colony counts were carried out the following day to determine relative biofilm
growth of S. aureus in the experimental vs control conditions. This procedure was later modified
by creating co-cultures with 1x, 2x, and 3x the concentration of the Alcaligenes species, allowing
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us to ascertain whether increasing the concentration of Alcaligenes cells decreases number of
viable S. aureus colonies in biofilms.
In the wells containing the cover slips, the coverslip containing the intact biofilm was
carefully removed, Gram-stained, and visualized under a microscope at 100x magnification.
Co-culture Supernatant Spot Testing
Overnight cultures of A. faecalis, A. viscolactis, S. aureus, and C. albicans were
prepared. As with the biofilm procedure, a spectrophotometer was used to create co-culture
samples with a 10:1 ratio of Alcaligenes to S. aureus or C. albicans. Of note, co-cultures with C.
albicans were prepared in BHI media for better growth. After 24 hours of growth, cell-free
supernatant from the co-cultures and from Alcaligenes, S. aureus, and C. albicans single cultures
were obtained by pelleting the cells on a tabletop centrifuge then filter sterilizing the remaining
solution with a 0.45 μm filter. Afterwards, 20 μL of the supernatant from the co-cultures were
spotted onto lawns of the test organism (S. aureus or C. albicans) along with controls of live
Alcaligenes cells, Alcaligenes supernatant, and S. aureus/C. albicans supernatant.
Broad-Spectrum Spot Testing
Spot tests were performed by pipetting 20 μL of an overnight culture of A. faecalis and A.
viscolactis on an LB agar plate streaked with a lawn of the test organism. After allowing the
plates to dry, they were placed at 37°C for 24-48 hours. Lawns of Rhizobium leguminosarum
ATCC #14479 were streaked on Congo Red and incubated at 30°C while Candida glabrata was
grown on BHI at 20-25°C because of different nutrient and growth requirements. Zones of
inhibition, if present, were measured and recorded.
New A. faecalis strains C19593 and ATCC #35655 were tested for antibiotic
susceptibility by placing antibiotic disks on a lawn of each strain on LB agar. Plates were
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incubated overnight. Liquid cultures of the strains were prepared, and 20 μL of each was spotted
onto a lawn of S. aureus clinical strain to determine if these other strains also possess the
inhibitory phenotype observed in A. faecalis ATCC #8750.
Transposon Mutagenesis
Overnight liquid cultures of A. faecalis, A. viscolactis, and E. coli BW20767 carrying the
pRL27 plasmid were prepared in 5 mL of LB broth. Several methods were then used to induce
mating. All overnight incubations were carried out at 37°C except with A. viscolactis cultures.
Cross Hatch Technique: Each Alcaligenes sp. was crossed with the pRL27 strain on an
LB agar plate using sterile cotton swabs. After incubation for 24 hours, 1 mL of PBS was added
to the plate, and the colonies were scraped into the solution using a sterilized hockey stick.100
μL of this solution was then plated onto an LB agar plate containing Kanamycin and Ampicillin
(LB + KA) at concentrations of 50 μg/ml each and incubated for 24 hours. Isolated colonies were
transferred to a fresh LB + KA plate using sterile toothpicks and allowed to grow again before
spot testing against S. aureus.
Liquid Co-culture Technique: 10 μL of pRL27 and 30 μL of Alcaligenes were added to a
5 mL LB tube and placed on a shaker. After 24 hours of growth, 100 μL of the co-culture was
plated on LB + KA and again incubated. As before, isolated colonies were transferred to a fresh
LB+KA and allowed to grow before phenotype screening.
Spot Co-culture Technique: Using overnight liquid cultures, 500 μL of Alcaligenes and
pRL27 were mixed in a microcentrifuge tube and pelleted in a tabletop centrifuge. After
resuspending in 200 μL of LB, 20 μL of the concentrated co-culture was spotted onto a fresh LB
plate and incubated. A loopful of the bacteria was inoculated into a 5 mL LB tube the next day
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and plated on LB + KA selective media. Further isolation of suspected mutants were carried out
as in the previous techniques.
In Silico Analysis of A. faecalis Genome Sequences
Using the National Center for Biotechnology Information (NCBI) GenBank, multiple
strains of A. faecalis were analyzed for presence of T6SS genes. Three strains, NTCC #10388,
BBD4, and ZD02, were primarily analyzed and later used to construct primers. A. faecalis
ATCC# 8750, our lab’s strain, has not been fully sequenced and could not be used for complete
genetic analysis.
Primer Design
The primers used in this study (Table 2) were designed largely by hand with the help of
NCBI Primer Blast and New England Biolab’s Tm Calculator.
Name

Sequence (5’ – 3’)

Use

VgrG-par-F

GCTGACAGAACGCCTTGTAC

Partial VgrG amplification

VgrG-par-R

CGATACGTGTAGAAGCGGTC

Partial VgrG amplification

VgrG-tot-F

GCTGACAGAACGCCTTGTAC

Total VgrG amplification

VgrG-tot-R

GATACACCGCACTGGTCTTG

Total VgrG amplification

AF-Hcp-F

TCCAGTCCTTTTCATGGGGC

Hcp Amplification

AF-Hcp-R

TGCTTGATATCCCAGGCCAC

Hcp Amplification

SOEF1

CGATGGTACCGAGTGGTTCATGCCTTGCAG

Upstream SOE Forward Primer

SOER2

CGAGGACTAAGAATACGCTGGACGGTACAA
GGCGTTCTGTCAG

Upstream SOE Reverse Primer

SOEF2

CCGTCCAGCGTATTCTTAGTCCTCGGATCAA
GACCAGTGCGGTG

Downstream SOE Forward
Primer

SOER1

GCTATCTAGATGGACGTTGCCCAAATACAGC

Downstream SOE Reverse
Primer

Table 2: Primers designed and used for this study.
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Genomic Extraction
Genomic extraction was completed using 2 mL of an overnight culture of A. faecalis and
a Promega Wizard gDNA purification kit. Extracted gDNA was tested for purity and
concentration using a Thermo Scientific nanodrop and stored at 4°C or -20°C.
Detection of VgrG via PCR and Electrophoresis
Aliquots containing primers pairs VgrG-par-F/VgrG-par-R and VgrG-tot-F/VgrG-tot-R
along with 1 μg of gDNA, nuclease free H2O, and NEB 2X Taq Polymerase Master Mix were
prepared to amplify partial and total sequences of the VgrG gene respectively. PCR parameters
were adjusted until optimal conditions were reached (Table 3). PCR products were loaded on a
1% agarose gel containing Ethidium Bromide at a concentration of 0.7 μg/mL, run at 125V for
40-45 minutes, and visualized under UV light. The Hcp gene was later amplified under the same
PCR conditions (Table 3).
Step
Initial Denaturation

Temp
95°C

Time
2 minutes

34 cycles

95°C
52°C
72°C

30 seconds
30 seconds
1 minute/kb

Final Extension

72°C

5 minutes

Hold
4°C
∞
Table 3: PCR thermocycler protocol for amplification of VgrG and Hcp genes.
DNA Extraction & Sequencing
Following amplification, 50 μL aliquots of PCR product were extracted from a 1%
agarose gel containing no Ethidium Bromide and purified using a Thermofisher gel extraction
kit. Purity and concentration of the extracted DNA were analyzed by nanodrop and by running 23 μL of the samples on another 1% agarose gel. The extracted DNA was sent to Quillen College
18

of Medicine’s Molecular Biology Core Facility for sequencing along with 15 μL each of the
appropriate primers diluted to a working concentration of 3μM.
Analysis of DNA Sequences
Sequencing results were cleaned and analyzed using NCBI Nucleotide Blast, Emboss
Merger, EMBOSS Needle, and a reverse complement generator acquired from
Bioinformatics.org.
Splicing by Overlap Extension
Splicing by Overlap Extension (SOE) is a method in which regions flanking the gene of
interest (approximately 1,000 base pairs (bp) upstream and downstream) are amplified via PCR
and fused together, thereby deleting out the gene [42]. This construct can then be ligated into a
vector and transferred into the species containing the gene of interest. From there, homologous
recombination replaces the original sequence, creating a knockout mutant. This technique was
used in an attempt to delete the VgrG gene in A. faecalis. Primers were designed using the A.
faecalis genomic sequences noted earlier and previously designed overlap/restriction enzyme
sequences [43]. Primer pairs SOEF1 – SOER2 were used to amplify a 944 bp sequence upstream
of VgrG while primer pairs SOEF2 – SOER1 were used to amplify a 1,041 bp sequence
downstream using the PCR parameters outlined previously (Table 3). Once the upstream and
downstream products were purified via gel extraction, a second, two-step PCR reaction was run,
splicing the fragments together and generating an approximately 2,000 bp product with a
deletion of VgrG (Tables 4 & 5). Following a second purification, the ends of this 2 kb fragment
and extracted pEX18Gm plasmid vector were digested using KpnI and XbaI restriction enzymes.
pEX18Gm is a plasmid vector containing a Gentamicin (GmR) resistance marker, pUC
polylinker, and SacB counterselectable marker [41]. After subsequent column purification of
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both the vector and insert, ligation using T4 DNA ligase was carried out using a 1:3 picomolar
ratio of vector to insert following a protocol from New England Biolabs (NEB). Integration of
the SOE product into pEX18Gm formed pEX18GmΔVgrG. Competent NEBα5 E. coli cells were
prepared using the Rubidium Chloride (RbCl2) protocol obtained from Mcmanus Lab. The
ligation product was used to transform pEX18GmΔVgrG into competent NEBα5 cells via a heat
shock protocol obtained from NEB. Cells successfully transformed with pEX18GmΔVgrG were
isolated using blue-white screening on LB agar plates containing 20 μg/mL of Gentamicin and
20 μg/mL of 5-bromo-4-chloro-3-indolyl-β-d-galactopyranoside (X-gal).
Plasmid vector pEX18Gm contains a LacZα gene, which encodes for β-galactosidase, at
its multiple cloning site [41]. When treated with X-gal, cells containing the non-recombinant
plasmid express a functional β-galactosidase that cleaves X-gal, forming a bright blue pigment.
Insertion of DNA into the multiple cloning site disrupts the LacZα gene, and the blue pigment is
not produced upon treatment with X-gal and appear white [44]. White colonies were re-plated,
and presence of the SOE product was confirmed by colony PCR using primer pair SOEF1SOER1.
Mixture 1 (25 μL)

Step

Temp

Time

Upstream Template (2 μL)

Initial Denaturation

95°C

3 minutes

Downstream Template (1 μL)

15 cycles

95°C
52°C
72°C

45 seconds
45 seconds
2.25 minutes

Final Extension

72°C

10 minutes

Taq 2X Master Mix (12.5 μL)
Sterile H2O (9.5 μL)

Hold
4°C
Table 4: Crossover reaction 1 setup and thermocycler protocol.
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∞

Mixture 2 (50 μL)
Product from Reaction 1 (25 μL)

Step
Initial Denaturation

Temp
95°C

Time
1 minutes

SOEF1 Primer (0.5 μL)

30 cycles

95°C
52°C
72°C

45 seconds
45 seconds
2.25 minutes

Final Extension

72°C

10 minutes

SOER1 Primer (0.5 μL)
Taq 2X Master Mix (12.5 μL)

Sterile H2O (11.5 μL)
Hold
4°C
Table 5: Crossover reaction 2 setup and thermocycler protocol.

∞

Transfer of pEX18GmΔVgrG to A. faecalis
NEBα5 cells harboring pEX18GmΔVgrG were then used for triparental conjugation with
pRK2013 and A. faecalis ATCC #8750 to transfer the deletion product to A. faecalis. Overnight
cultures of the three strains were grown in antibiotic-containing LB broth, ensuring their purity.
NEBα5 was grown in 20 μg/mL of Gentamicin, pRK2013 in 50 μg/mL of Kanamycin, and A.
faecalis in 35 μg/mL of Ampicillin. One microliter of each culture was pelleted using a tabletop
centrifuge and washed twice with sterile 0.85% NaCl to remove any residual antibiotics. After
resuspending in 200 μL of saline, 100 μL of each strain was mixed, pelleted, and resuspended in
30 μL of saline or filter sterilized PBS. This mixture was spotted in 10-15 μL aliquots either
directly onto LB agar or onto a 0.45 μm nitrocellulose filter disk resting on the agar, and the
plates were allowed to incubate for 24 hours at 37 °C. After incubation, the mixture was
resuspended in 1 mL of PBS by using an inoculation loop or vortexing the filter disk. Tenfold
dilutions were then performed and plated on LB + Gm20 agar. Following incubation for 24-48
hours, isolated colonies were re-plated on selective agar and screened via colony PCR. The
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pEX18GmΔVgrG plasmid was also transformed into RbCl2 competent E. coli SM10λpir cells by
heat shock and biparental mating was carried out following the same procedure as above without
use of the pRK2013 strain.
RESULTS & DISCUSSION
Biofilm Interactions
Results from the biofilm co-culture assays reveal that both A. faecalis and A. viscolactis
are able to outcompete S. aureus when grown together and cause a significant reduction in the
growth of viable S. aureus cells during the attachment phase of biofilm formation. Co-culturing
clinical S. aureus with A. viscolactis at a 1:10 ratio resulted in a 97.2% decrease in viable cells
while co-culturing S. aureus with A. faecalis at the same ratio resulted in a 96.1% decrease (Fig.
1 & 2). Doubling the concentration of A. viscolactis and A. faecalis resulted in S. aureus
reductions of 98.3% and 97.6% respectively (Fig. 1 & 2). Surprisingly, tripling the concentration
of Alcaligenes failed to significantly decrease S. aureus growth even further and the number of
surviving S. aureus cells rose slightly in the assays with A. faecalis. This demonstrates that while
inhibition of S. aureus biofilms by Alcaligenes follows a concentration-dependent manner, this
effect is limited and seems to slow or stop once a certain concentration of cells is reached. A
plausible explanation for this observation may be that at high concentrations, rapid depletion of
resources occurs, which in turn may effect Alcaligenes’ ability to prey on other organisms.
Gram-stains of the control vs experimental co-cultures visualized with light microscopy at 100x
magnification demonstrates the effectiveness of Alcaligenes at disrupting S. aureus biofilm
growth (Fig. 3). Of note, these results show that A. viscolactis, whose optimum temperature
growth is 20-25°C, does not appear to lose its inhibitory function when incubated at 37°C.
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Figure 1: Viable S. aureus colonies on Mannitol Salt Agar after 24 hours at 37°C from washed
biofilms. Biofilms were grown for 24 hours at 37°C under control conditions with our clinical S.
aureus strain alone and under experimental conditions with our clinical S. aureus strain cocultured with one, two, and three times concentrations of A. viscolactis. Mean log10 CFU/mL
data were obtained from three separate trials, and statistical analysis was performed using onetailed, unpaired Student T-tests comparing the control condition to each of the three experimental
conditions. Standard error bars are also included for analytical purposes. * = p < 0.05, ** = p <
0.01, *** = p < 0.005.
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Figure 2: Viable S. aureus colonies on Mannitol Salt Agar after 24 hours at 37°C from washed
biofilms. Biofilms were grown for 24 hours at 37°C under control conditions with our clinical S.
aureus strain alone and under experimental conditions with our clinical S. aureus strain cocultured with one, two, and three times concentrations of A. faecalis. Mean log10 CFU/mL data
were obtained from three separate trials, and statistical analysis was performed using one-tailed,
unpaired Student T-tests comparing the control condition to each of the three experimental
conditions. Standard error bars are also included for analytical purposes.
* = p < 0.05, ** = p < 0.01, *** = p < 0.005.
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(a)

(b)

(c)

(d)

Figure 3: Gram-stains of biofilms grown for 24 hours and visualized at 100x: (a) S. aureus
clinical strain (SAC), (b) co-culture of S. aureus clinical and 1x concentration of A. faecalis, (c)
S. aureus clinical strain, (d) co-culture of S. aureus clinical and 1x concentration of A.
viscolactis.
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Confirmation of a Contact-dependent Mechanism
To supply further proof that Alcaligenes’ method of inhibition is contact-dependent and
not due to secretion of an antimicrobial compound only in the presence of a competing organism,
cell-free supernatant from co-cultures of A. faecalis or A. viscolactis and S. aureus or C. albicans
were spotted onto lawns of the test organism along with controls of live Alcaligenes cells,
Alcaligenes supernatant, and S. aureus/C. albicans supernatant. As hypothesized, only live
Alcaligenes cells formed zones of inhibition on both S. aureus and C. albicans, confirming the
requirement of live contact of Alcaligenes with its microbial prey (Fig. 4 & 5).

Figure 4: Co-culture-supernatant test: (a) A. faecalis cells, (b) A. faecalis supernatant, (c) C.
albicans supernatant, (d) A. faecalis - C. albicans co-culture supernatant, (e) A. faecalis cells, (f)
A. faecalis supernatant, (g) S. aureus supernatant, (h) A. faecalis - S. aureus co-culture
supernatant.
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Figure 5: Co-culture-supernatant test: (a) A. viscolactis cells, (b) A. viscolactis supernatant, (c)
C. albicans supernatant, (d) A. viscolactis - C. albicans co-culture supernatant, (e) A. viscolactis
cells, (f) A. viscolactis supernatant, (g) S. aureus supernatant, (h) A. viscolactis - S. aureus coculture supernatant.
Spectrum of Alcaligenes Inhibitory Activity
While previous research had shown that both A. faecalis and A. viscolactis are significant
inhibitors of C. albicans and Staphylococcus species, it was still unclear whether they were
active against other microorganisms. Both Alcaligenes strains were spot-tested on a variety of
other microbial species (Table 6). A. faecalis was found to be a relatively strong inhibitor of
members of the genus Bacillus, including the pathogenic B. cereus. (Fig. 6). Interestingly,
preliminary testing shows that A. faecalis also kills Candida glabrata, though not to the degree
that it does C. albicans, which may be at least explained in part by C. glabrata’s yeast
morphology and lack of morphological switching into hyphal form as in C. albicans [45]. This
would be consistent with previous observations in our lab of decreased inhibition of C. albicans
in yeast-locked strains. Moreover, Alcaligenes viscolactis exhibited a lesser effect on these
species with only B. subtilis being visually inhibited (Fig. 7). In addition, Klebsiella pneunoniae,
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Shigella dysenteriae, and Shigella sonnei showed a small degree of sensitivity to A. faecalis but
none to A. viscolactis (Fig. 6). We also noted that the Gram-negative Rhizobium leguminosarum
was strongly inhibited by both Alcaligenes species, and that it does not appear that A. faecalis
and A. viscolactis inhibit each other’s growth.
Inhibition by Inhibition by
A. faecalis
A. viscolactis
B. cereus
++
B. megaterium
+++
Gram-positive
B. subtilis
+++
+
E. faecalis
S. aureus
+++
++
S. pyogenes
C. albicans
+++
++
Fungal
nd*
C. glabrata
+
C. freundii
E. coli BW20767/prRL27
Escherichia coli ATCC #25922
Klebsiella aerogenes
Klebsiella pneumoniae
+
Proteus vulgaris
Pseudomonas aeruginosa
Gram-negative
Pseudomonas denitrificans
Rhizobium leguminosarum
+++
+++
Salmonella arizonae
Salmonella typhi
Serattia marcescens
Shigella boydii
Shigella dystenteriae
+
Shigella sonnei
+
Table 6: Spot-Test Assays of A. faecalis and A. viscolactis on broad range of organisms (* not
determined from spot test).
Classification

Species

28

(a)

(b)

(c)

(d)

(e)

Figure 6: Zones of inhibition of A. faecalis on lawns of (a) B. megaterium (b) B. subtilis (c) B.
cereus (d) R. leguminosarum (e) Candida glabrata.

(a)

(b)

Figure 7: Zones of inhibition of A. viscolactis on lawns of (a) B. subtilis (b) R. leguminosarum.
These observations raise a pertinent question. While both A. faecalis and A. viscolactis
have been shown to have live-cell dependent, microbicidal effects on a number of organisms,
what explains the significant difference in their activity when spot-tested on certain species? One
hypothesis is that incubation at 37°C to allow the test organism to grow may stunt the growth of
A. viscolactis or its expression of intracellular machinery needed to kill more resistant organisms.
Results from the biofilm assays appear to contradict this explanation, however. Additionally, its
lack of motility and slower growth rate compared to A. faecalis may also explain its lesser
activity when using a spot-test assay, suggesting that co-culture colony counts may be a better
mechanism for determining spectrum of inhibition for A. viscolactis.
Mutagenesis with pRL27
Transposon mutagenesis is a technique that uses conjugation to transfer a plasmid
containing a transposon element into the desired bacterium. Once inside the cell, the transposon
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segment of the plasmid randomly inserts once into the bacterial chromosome with the help of a
transposase enzyme, disrupting the gene at the point of insertion. This technique is incredibly
valuable for identification of unknown genes integral for a specific function. In this case, E. coli
strain BW20767 carrying plasmid vector pRL27 was used for conjugation to transport the Tn5
transposon into A. faecalis and A. viscolactis [40]. The pRL27 plasmid also contains a Kmr gene,
which confers Kanamycin resistance to both the donor strain and the mutant upon insertion of
the transposon [40]. This enables simple isolation of mutants via growth on antibiotic plates.
Kirby-Bauer testing was performed on E. coli-pRL27 and on both Alcaligenes species to create
an antibiotic susceptibility profile (Table 7).

Antibiotic

Concentration
(MCG)
Ampicillin
10
Bacitracin
10
Chloramphenicol 30
Erythromycin
15
Kanamycin
30
Novobiocin
5
Penicillin
10
Streptomycin
10
Tetracycline
30

E. coli pRL27
Susceptibility
+
+
+
+

A. faecalis
Susceptibility
+
+
+
n/a
+
+

A. viscolactis
Susceptibility
+
+
+

Table 7: Susceptibility Profile of E. coli pRL27, A. faecalis, and A. viscolactis to common
antibiotics.
Based on the results, Ampicillin and Kanamycin were chosen as the appropriate
antibiotics for the selection of mutants. Both Alcaligenes species are resistant to Ampicillin while
E. coli pRL27 is not, which allows only the growth of Alcaligenes. Since mutants contain the
KmR gene, treatment with Kanamycin will inhibit growth of all Alcaligenes cells except for
exconjugants with the transposon inserted into its genome. Despite successful mutagenesis of
Klebsiella pneumoniae ATCC #13883 using E. coli pRL27 by others in our lab, no mutants of
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either A. faecalis or A. viscolactis were obtained by any of the three techniques outlined earlier
[46]. While isolated colonies appeared on plates left in the incubator for longer than 48 hours,
they either failed to grow when re-plated on selective media or were determined to be
Staphylococcal contaminants by Gram-staining. The repeated occurrence of contaminants
suggest either a breakdown of antibiotics past 48-72 hours or colonization by a strain of
Staphylococcus resistant to both antibiotics used. Despite numerous screenings, no true
Alcaligenes mutants were obtained via transposon mutagenesis.
In Silico Analysis of A. faecalis Genomic DNA
Using NCBI’s genomic database and protein BLAST function, the genomes of several
fully sequenced A. faecalis strains were analyzed for the presence of T6SS genes. Core genes of
conserved T6SS components as well as other proteins of unknown function were found clustered
at a single locus in several A. faecalis strains (Table 8). Of the essential TssA-TssM genes, all
except for TssH were found in every genome containing the T6SS locus. Whether the sheath
recycling function of TssH in A. faecalis is not critical to its T6SS functioning or is sometimes
replaced by another protein is currently unknown. Interestingly, an unidentified protein
containing a Duf4150 domain was also found within this locus. In certain proteobacteria such as
Agrobacterium tumefaciens, this N-terminal domain caps the end of the spike formed by VgrG,
while the C-terminal contains a toxin_43 domain that functions as a DNase [47]. Despite the
conserved Duf4150 domain, no homology to the toxin_43 domain could be found in A. faecalis,
suggesting the C-terminal of this protein may possess a different function as a possible effector
molecule.

31

Gene/Component

Conserved/Proposed Function
Baseplate

Source
TssA
Cianfanelli
et al.
Contractile Sheath: Small
Contractile Sheath
Cianfanelli
Subunit (TssB)
et al.
Contractile Sheath: Large
Contractile Sheath
Cianfanelli
Subunit (TssC)
et al.
Hcp (TssD)
Expelled Tube
Cianfanelli
et al.
TssE
Baseplate
Cianfanelli
et al.
TssF
Baseplate
Cianfanelli
et al.
TssG
Baseplate
Cianfanelli
et al.
TssH*
Sheath Recycling/ATPase
Cianfanelli
et al.
VgrG (TssI)
Expelled Spike
Cianfanelli
et al.
TssJ
Membrane Complex
Cianfanelli
et al.
TssK
Baseplate
Cianfanelli
et al.
DotU (TssL)
Membrane complex
Cianfanelli
et al.
TssM
Membrane complex
Cianfanelli
et al.
Protein with Duf4150 domain PAAR analogue - tip
Bondage
spike/Effector Toxin
et al.
Protein with Duf2169 domain Links VgrG to Effector Protein
Bondage
et al.
TagF
Post-translational regulation
Cianfanelli
et al.
Protein with FHA domain
Post-translational regulation
Cianfanelli
et al.
Table 8: T6SS Components Found in A. faecalis genome database and their conserved or
proposed function in the T6SS of studied bacteria, (* not present in the T6SS loci of all A.
faecalis strains).
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T6SS in A. faecalis ATCC 8750 and A. viscolactis Wards
Due to lack of a complete genome sequence for A. faecalis ATCC #8750, primers were
first designed to amplify a partial sequence and then the full sequence of the VgrG gene to
determine if a putative T6SS might be present in our laboratory’s strain. VgrG is an
approximately 2.3 kb gene that codes for a protein forming the spike of the T6SS. PCR and gel
electrophoresis confirmed presence of VgrG in A. faecalis ATCC #8750 and our strain of A.
viscolactis (Fig. 8a & 8b). Additionally, we later successfully amplified the Hcp (TssD) gene in
both A. faecalis and A. viscolactis (Fig. 8c). The Hcp gene encodes an essential protein that in
T6SS-containing organisms forms a hexameric inner tube structure that is later expelled upon
contraction. Because its genome sequence has never been recorded or published, these results are
the first to our knowledge that show evidence of a T6SS in A. viscolactis, further pointing to the
possibility that this system is responsible for the observed microbicidal phenotype of both
Alcaligenes species.
1 2 3
√ç

4

5 6

7 8

1

2

3

1 2 3 4 5

4

2322 bp
300 bp

400 bp

(a)
(b)
(c)
Figure 8: (a): Amplification of small VgrG fragment (276 bp): Lane 1: 100 bp ladder, lane 2-4:
A. faecalis gDNA, lane 6-8: A. viscolactis gDNA, (b) Amplification of large VgrG seq. (2.276
kb): Lane 1: λ DNA-HindIII ladder, Lane 2: A. faecalis gDNA, Lane 3: A. viscolactis gDNA, (c)
Amplification of Hcp (388 bp): Lane 1: 100 bp ladder, Lane 2: A. faecalis gDNA, Lane 3: A.
viscolactis gDNA.
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Sequencing of VgrG
Forward and reverse nucleotide sequences were merged using Emboss Merger and
compared to sequences in the NCBI genome database using BLAST. Th
The 273 bp sequence obtained from A. faecalis ATCC 8750 shared a 98.84% similarity
with the VgrG sequences from A. faecalis strains DSM30030 and FDAARGOS_491 and greater
than 92% similarity to other strains. The 275 BP sequence obtained from A. viscolactis shared
99.27% similarity with the VgrG sequences from A. faecalis strains DSM30030 and
FDAARGOS_491 and greater than 92% similarity to other A. faecalis strains. Using EMBOSS
Needle, both sequences were aligned and analyzed, and comparison revealed a 97.1% similarity
between the obtained VgrG sequences of A faecalis and A. viscolactis. While only a small
segment was successfully sequenced, these results confirm that the designed primers amplified
the VgrG gene and points to a high degree of similarity between the VgrG genes of both A.
faecalis and A. viscolactis (Fig. 9).

Figure 9: Alignment of A. faecalis and A. viscolactis partial VgrG sequences obtained from PCR
using constructed primer pair VgrGpF/VgrGpR.
34

Construction and Transfer of a VgrG Deletion Product via SOE
Because the VgrG gene encodes an essential part of the T6SS, construction of a VgrG
knockout mutant would allow us to determine what role, if any, the T6SS plays in the broadspectrum, antimicrobial phenotype displayed by A. faecalis and, by extension, A. viscolactis.
Using SOE primer pairs, approximately 1000 bp regions flanking VgrG in A. faecalis were
amplified via PCR (Fig. 10a). A second PCR reaction fused the two segments together, forming
a deletion product (Fig. 10b). This product was successfully ligated into pEX18Gm and
transformed into E. coli NEBα5 by heat shock. Blue/white screening and colony PCR both
confirmed presence of the recombinant plasmid carrying the SOE product (Fig. 10c & 11).
1

2

3

4

1

5

2

3

4

2 kb

5

1

2

3

4

5

6

2 kb

1 kb

(a)

(b)

(c)

Figure 10: Visualization of PCR amplification on 1% agarose gel with NEB 1 kb plus DNA
ladder: (a) Lanes 2-3: upstream SOE fragment, Lanes 4-5: downstream SOE fragment, (b) Lanes
2-5: SOE crossover product (c) Lanes 2-6: SOE product in transformed NEBα5 colonies.
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Transformants with SOE Insert

Transformants without
SOE Insert

Figure 11: Blue/White Screening for Recombinant NEBα5 Colonies Containing SOE VgrG
Deletion Product.
Triparental Mating
Despite successful construction and insertion of pEX18GmΔVgrG into NEBα5,
triparental mating with pRK2013 repeatedly failed to transfer the plasmid to A. faecalis.
Increasing incubation time to 48 hours and modifying incubation temperature from 37°C to 42°C
had no effect. Biparental mating with SM10λpir and A. faecalis was also attempted, and
conjugation was unsuccessful as before. Without the ability to insert plasmids into A. faecalis,
we were unable to create a VgrG knockout mutant and ascertain whether the putative T6SS of A.
faecalis is responsible for our observations. Despite hundreds of attempts by members of our lab
and using multiple methods including conjugation, heat shock, and electroporation, both A.
faecalis and A. viscolactis have proved resistant to horizontal gene transfer. Despite other
studies’ success using conjugation and electroporation with A. faecalis, strains other than ATCC
#8750 were used [48,49]. This raises the question as to whether this strain along with our lab’s
strain of A. viscolactis possess unknown barriers to the uptake of foreign DNA such as restriction
enzyme activity [50].
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Antibiotic Susceptibility and Phenotypic Profile of Other A. faecalis Strains
An antibiotic susceptibility profile for two new A. faecalis strains was carried out so that
a suitable selective media for conjugation could be determined (Table 9). Unlike strain #8750,
strains C19593, #35655, and Wards were resistant to Streptomycin in addition to Ampicillin,
Penicillin, and Bacitracin (Fig. 12). While these strains showed the greatest sensitivity to
Kanamycin, #35655 demonstrated a large decrease in sensitivity to Chloramphenicol,
Tetracycline, and Erythromycin (Fig 12b). All three strains retained the inhibitory phenotype
against clinical S. aureus (Fig. 13).
Antibiotic

Concentration A. faecalis C19593
(MCG)
Susceptibility
Ampicillin
10
Bacitracin
2
Chloramphenicol 30
+
Erythromycin
15
+
Kanamycin
30
+
Penicillin
10
Streptomycin
10
Tetracycline
30
+

A. faecalis #35655
Susceptibility
+
+
+
+

A. faecalis Wards
Susceptibility
+
+
+
+

Table 9: Susceptibility Profile of A. faecalis C19593 and A. faecalis ATCC #35655 to common
antibiotics.
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(a)

(b)

(c)

Figure 12: Antibiotic Susceptibility Profile of A. faecalis strains (a) C19593, (b) ATCC #35655,
and (c) Ward’s.

(a)

(b)

(c)

Figure 13: Spot-tests of A. faecalis strains (a) C19593, (b) ATCC #35655, and (c) Ward’s on
lawns on clinical S. aureus.
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CONCLUSION
Due to the rise of drug-resistance in bacterial and fungal species, the search for
innovative approaches to combating these often pathogenic organisms is urgent. The realm of
polymicrobial interactions is particularly promising as organisms have often developed
antimicrobial mechanisms to outcompete other species. One such system can be found in
Alcaligenes faecalis and Alcaligenes viscolactis, which has been found to inhibit S. aureus and
C. albicans via a microbicidal, contact-dependent mechanism. This thesis builds on these
previous findings, showing that both Alcaligenes species retain this ability when grown in a
biofilm with S. aureus and kill a broad range of organisms including C. glabrata and a variety of
Gram-positive and even Gram-negative bacteria. Additionally, it provides preliminary evidence
for the potential existence of a putative T6SS in A. faecalis and A. viscolactis, which may be
responsible for our observations. If implicated, this T6SS would be unique due its ability to
target not only eukaryotic Candida species and certain Gram-negative bacteria but also a range
of Gram-positive organisms, an ability not currently considered possible in the studied T6SS of
other bacteria [35]. Future studies of the T6SS in Alcaligenes faecalis may also lead to discovery
of a new class of effector molecules. Because of a consistent inability to induce plasmid transfer
via conjugation and other forms of gene transfer, the exact mechanism for Alcaligenes’
inhibitory effect remains elusive, and an entirely unknown system may be at play. Future
directions include RNA isolation and analysis for upregulation of T6SS genes during co-cultures
and use of newly acquired A. faecalis strains for transposon and site-directed mutagenesis.
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